ArticleScientific reports2025

Risk of tuberculosis and hepatitis B reactivation during adalimumab use in the treatment of hidradenitis suppurativa.

Ömer Karakoyun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.